Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature.

Carlotta BecheriniViola SalvestriniIsacco DesideriGiulia VagnoniIlaria BonaparteNiccolò BertiniChiara MattioliLucia AngeliniLuca VisaniVieri ScottiLorenzo LiviSaverio CainiPierluigi Bonomo

Published in: La Radiologia medica (2024)

The use of fosaprepitant in preventing CINV reduced incidence of moderate to severe nausea and vomiting. No correlation has been found between nausea and median dose to DVC and AP.

Keyphrases

chemotherapy induced
patients undergoing
rectal cancer
risk factors
transcription factor
high intensity
early onset
locally advanced
study protocol
drug induced